

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Infectious disease; inflammation	IL-22	<p>Mouse studies suggest IL-22 could help improve thymic recovery following infection or immunodepletion. Thymic recovery following total body irradiation was impaired in <i>Il-22</i>-deficient mice compared with that in either <i>Il-22</i>-deficient mice treated with recombinant IL-22 or wild-type mice. In the <i>Il-22</i>-deficient mice, recombinant IL-22 increased thymic recovery synergistically with hematopoietic stem cell transplant (HSCT) compared with saline control. Next steps include studying the impact of IL-22 on immune recovery following HSCT.</p> <p>SciBX 5(11); doi:10.1038/scibx.2012.288 Published online March 15, 2012</p>	Patent application filed for use of IL-22 as a thymopoietic growth factor; available for licensing	<p>Dudakov, J.A. <i>et al. Science</i>; published online March 1, 2012; doi:10.1126/science.1218004 Contact: Jarrod A. Dudakov, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: dudakovj@mskcc.org Contact: Marcel R.M. van den Brink, same affiliation as above e-mail: vandenbm@mskcc.org</p>